Stocksigma LogoStocksigma Logo

GSK India Reports Strong Q2 FY27 With PAT Up 31% YoY

GlaxoSmithKline Pharmaceuticals reported revenue of INR 1,180 crore for Q2 FY27 ended 30th Sep'26, up 21% YoY, supported by General Medicines, Vaccines

GSK India Reports Strong Q2 FY27 With PAT Up 31% YoY

GlaxoSmithKline Pharmaceuticals Ltd 路 Press Release 路 04 Nov 2026, 12:32 am

GSK India Reports Strong Q2 FY27 With PAT Up 31% YoY GlaxoSmithKline Pharmaceuticals reported revenue of INR 1,180 crore for Q2 FY27 ended 30th Sep'26, up 21% YoY, supported by General Medicines, Vaccines, and Specialty portfolios alongside a favorable base effect. EBITDA rose 20% YoY, while PAT increased 31% YoY to INR 335 crore. Core brands Augmentin, Calpol, Ceftum, and T-bact gained market share, while Shingrix drove adult vaccine growth. The company announced its entry into haemato-oncology with the planned launch of BLENREP for relapsed or refractory multiple myeloma, building on its existing oncology footprint.

Original exchange filing (PDF)

More announcements from GlaxoSmithKline Pharmaceuticals Ltd

All GlaxoSmithKline Pharmaceuticals Ltd announcements